Skip to main content

Table 3 Univariate and multivariate analyses of prognostic factors for disease-free survival and overall survival in 184 patients with mid/low rectal cancer

From: Total mesorectal excision with or without preoperative chemoradiotherapy for resectable mid/low rectal cancer: a long-term analysis of a prospective, single-center, randomized trial

Variable 5-year DFS rate 5-year OS rate
Univariate Multivariate Univariate
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Age (> 60 vs. ≤ 60 years) 0.545 (0.249–1.194) 0.129    0.862 (0.425–1.748) 0.681
Sex (male vs. female) 0.878 (0.460–1.677) 0.694    0.758 (0.397–1.444) 0.399
DAV (≤ 5 cm vs. > 5 cm) 0.698 (0.361–1.315) 0.259    0.834 (0.488–1.783) 0.834
pT stage (3–4 vs. 0–2) 2.940 (1.344–6.434) 0.007 2.242 (0.987–5.093) 0.054 2.365 (1.115–5.018) 0.025
pN stage (1–2 vs. 0) 2.903 (1.519–5.546) 0.001 2.281 (1.157–4.495) 0.017 1.801 (0.939–3.453) 0.076
Type of resection (LAR vs. APR) 0.983 (0.485–1.989) 0.961    0.693 (0.356–1.348) 0.280
Perioperative chemotherapy cycles (≤ 6 vs. > 6) 2.124 (0.971–4.646) 0.059    1.381 (0.682–2.798) 0.370
Treatment (CCRT + TME vs. TME) 1.030 (0.540–1.963) 0.929    0.887 (0.461–1.707) 0.720
  1. DFS, disease-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; DAV, distance of the inferior tumor margin from the anal verge; pT stage, pathologic tumor stage; pN stage, pathologic node stage; LAR, low anterior resection; APR, abdominoperineal resection; TME, total mesorectal excision; CCRT, concurrent chemoradiotherapy
  2. Italic values indicate significance of p vaule (p < 0.05)